News - Eli Lilly, Cardio-vascular


Current filters:

Eli LillyCardio-vascular

Popular Filters

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP


At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbasriaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient


UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022


The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST


In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study


Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo files for Japanese approval of Prasugrel


Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

EMA starts review of Merck & Co's cholesterol drug Tredaptive


The European Medicines Agency said on December 21 that it has started a review of the safety and efficacy…

anacetrapibCardio-vascularEli LillyEuropeevacetrapibMerck & CoPharmaceuticalRegulationTredaptive

STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that ticagrelor, its oral antiplatelet…

AstraZenecaBrilintaBriliqueCardio-vascularEffientEli LillyPharmaceuticalRegulation

Anti-clotting drugs prasugrel and clopidogrel yield similar results


The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Lilly and Kowa's Livalo meets primary endpoint of LDL-C reduction


Presenting at the National Lipid Association's (NLA) Scientific Sessions in Scottsdale, Arizona, USA,…

Cardio-vascularEli LillyKowa PharmaceuticalsLivaloPharmaceuticalResearch

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa


Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

New Zealand approves Effient listing for clopidogrel-allergic patients


The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015


The acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010…

AstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalSouth America

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015


The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect


Byetta (exenatide), a drug which has been co-developed and now marketed by US biotech firm Amylin (Nasdaq:…

AmylinByettaCardio-vascularDiabetesEli LillyPharmaceuticalResearch

Back to top